Magnitude and time course of urinary iodine excretion in patients after amiodarone therapy.

IF 2.5 Q3 ENDOCRINOLOGY & METABOLISM Minerva endocrinology Pub Date : 2024-07-22 DOI:10.23736/S2724-6507.24.04213-1
Giulia Marchionni, Giuseppe Pinto, Massimo Locatelli, Roberto Spoladore, Luca Foppoli, Giuseppe Monaca, Alberto Margonato, Gabriele Fragasso
{"title":"Magnitude and time course of urinary iodine excretion in patients after amiodarone therapy.","authors":"Giulia Marchionni, Giuseppe Pinto, Massimo Locatelli, Roberto Spoladore, Luca Foppoli, Giuseppe Monaca, Alberto Margonato, Gabriele Fragasso","doi":"10.23736/S2724-6507.24.04213-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Amiodarone is a source of iodine excess that may persist in the body for long time after its withdrawal. The aim of the present analysis was to evaluate the magnitude and long-term time course of 24-h urinary iodine (UI) excretion in patients on antiarrhythmic therapy with amiodarone.</p><p><strong>Methods: </strong>24-h UI excretion and thyroid function were evaluated in 67 patients on amiodarone therapy. All patients were clinically and biochemically euthyroid before starting treatment and were followed-up by 6-month measurements of 24-h UI excretion and plasma thyroid hormones levels.</p><p><strong>Results: </strong>Upon amiodarone withdrawal, normal range of UI was achieved after a mean time of 15.2±7.7 months. Since amiodarone initiation, 20 patients developed thyroid dysfunction. No differences were observed in terms of treatment length or median UI levels between patients remaining euthyroid and those developing thyroid dysfunction: median UI in the euthyroid group was 8094 µg/24 h (Interquartile Range [IQR]: 4082-10766) vs. 10851 µg/24 h (IQR: 8529-12804) in the thyroid dysfunction group at 6 months (P=0.176) and 8651 µg/24 h (IQR: 6924-11574) vs. 8551 µg/24 h (IQR: 4916-13580) at one year from amiodarone initiation (P=0.886). The occurrence of thyroid dysfunction was equally distributed among patients taking amiodarone for more than one year versus those under treatment for less than one year.</p><p><strong>Conclusions: </strong>These results confirm the long-lasting total-body iodine stores and consequent excretion in patients after amiodarone withdrawal. These long-lasting iodine stores might be taken into special account in patients necessitating therapy with radioactive iodine and for long-term monitoring of thyroid function after amiodarone discontinuation.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23736/S2724-6507.24.04213-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Amiodarone is a source of iodine excess that may persist in the body for long time after its withdrawal. The aim of the present analysis was to evaluate the magnitude and long-term time course of 24-h urinary iodine (UI) excretion in patients on antiarrhythmic therapy with amiodarone.

Methods: 24-h UI excretion and thyroid function were evaluated in 67 patients on amiodarone therapy. All patients were clinically and biochemically euthyroid before starting treatment and were followed-up by 6-month measurements of 24-h UI excretion and plasma thyroid hormones levels.

Results: Upon amiodarone withdrawal, normal range of UI was achieved after a mean time of 15.2±7.7 months. Since amiodarone initiation, 20 patients developed thyroid dysfunction. No differences were observed in terms of treatment length or median UI levels between patients remaining euthyroid and those developing thyroid dysfunction: median UI in the euthyroid group was 8094 µg/24 h (Interquartile Range [IQR]: 4082-10766) vs. 10851 µg/24 h (IQR: 8529-12804) in the thyroid dysfunction group at 6 months (P=0.176) and 8651 µg/24 h (IQR: 6924-11574) vs. 8551 µg/24 h (IQR: 4916-13580) at one year from amiodarone initiation (P=0.886). The occurrence of thyroid dysfunction was equally distributed among patients taking amiodarone for more than one year versus those under treatment for less than one year.

Conclusions: These results confirm the long-lasting total-body iodine stores and consequent excretion in patients after amiodarone withdrawal. These long-lasting iodine stores might be taken into special account in patients necessitating therapy with radioactive iodine and for long-term monitoring of thyroid function after amiodarone discontinuation.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
胺碘酮治疗后患者尿碘排泄量的大小和时间进程。
背景:胺碘酮是碘过量的来源之一,停药后可能在体内长期存在。本分析旨在评估接受胺碘酮抗心律失常治疗的患者 24 小时尿碘(UI)排泄量的大小和长期时间过程。所有患者在开始治疗前在临床和生化方面均为甲状腺功能正常,并接受了为期 6 个月的 24 小时尿失禁排泄物和血浆甲状腺激素水平的随访:结果:停用胺碘酮后,平均 15.2±7.7 个月后尿量达到正常范围。自开始使用胺碘酮以来,20 名患者出现了甲状腺功能障碍。保持甲状腺功能正常的患者和出现甲状腺功能障碍的患者在治疗时间和 UI 中位数水平方面没有发现差异:甲状腺功能正常组的 UI 中位数为 8094 µg/24 h(四分位距 [IQR]:4082-10766),而甲状腺功能障碍组的 UI 中位数为 10851 µg/24 h(四分位距 [IQR]:4082-10766)。甲状腺功能障碍组在开始使用胺碘酮 6 个月时的 UI 中位数为 10851 µg/24 h(IQR:8529-12804)(P=0.176),一年后的 UI 中位数为 8651 µg/24 h(IQR:6924-11574)与 8551 µg/24 h(IQR:4916-13580)(P=0.886)。服用胺碘酮一年以上的患者与治疗不到一年的患者发生甲状腺功能障碍的比例相当:这些结果证实,停用胺碘酮后,患者体内的总碘储量会长期存在,并随之排出体外。对于需要使用放射性碘治疗的患者,以及停用胺碘酮后长期监测甲状腺功能的患者,这些长期的碘储存可能会被特别考虑。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.60
自引率
0.00%
发文量
146
期刊最新文献
Diet quality in patients with treatment-resistant schizophrenia: time for improving nutritional recommendations. Zebrafish model in the relentless race to tyrosine kinase inhibitors for neuroendocrine neoplasms. Assessing the impact of a dedicated referral and management algorithm in maternal hypothyroidism. Divulging the overlooked condition: diabetic ketoacidosis as an imminent risk with sodium-glucose co-transporter-2 inhibitors treatment in type 2 diabetes mellitus. Obesity prevention across the lifespan: assessing the efficacy of intervention studies and discussing future challenges.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1